Camillla Fuchs Andersen

7PUBLICATIONS
27CO-AUTHORS
Major global burdens of diseaseNutritional epidemiologyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Epidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 09, 2026
Care and Outcomes of New-Onset Heart Failure Across Vulnerable Populations: Temporal Trends in Mortality and Treatment in a Danish Nationwide Cohort From 2003 to 2022.

Sofie-Louise Feentved Ødum, Clara Friis, Caroline Hartwell Garred

|Jan 08, 2026
Effects of empagliflozin in patients at risk of heart failure: the Empire Prevent Metabolic Trial.

Camilla Fuchs Andersen, Julie Hempel Larsen, Massar Omar

|Feb 03, 2025
Temporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk Score.

Noor K Abassi, Nina Nouhravesh, Mariam Elmegaard

|Jan 24, 2023
Letter regarding the article 'Little at a time: trying to understand the battery of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure'.

Camilla Fuchs Andersen, Andreas Glenthøj, Jesper Jensen

|Dec 09, 2022
Reduction of cardiac adipose tissue volume with short-term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial.

Niels H Brandt-Jacobsen, Mikkel Jürgens, Philip Hasbak

|Nov 15, 2022
Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial.

Camilla Fuchs Andersen, Massar Omar, Andreas Glenthøj

Pageof 2

Frequent Collaborators

3 joint publications

Morten Schou

3 joint publications

Lars Køber

2 joint publications

Nina Nouhravesh

2 joint publications

Marte Austreim